Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad GeneticsSTU:MYD -6.00%59 Debt-to-EBITDA is -2.02 as of Jun. 2026. GuruFocus rates STU:MYD with a GF Score™ of 59/100 and a GF Value™ of €10.07 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 877192.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Myriad Genetics's Debt-to-EBITDA or its related term are showing as below:
STU:MYD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.66 Med: -0.63 Max: 7.5
Current: -4.66
During the past 13 years, the highest Debt-to-EBITDA Ratio of Myriad Genetics was 7.50. The lowest was -4.66. And the median was -0.63.
STU:MYD's Debt-to-EBITDA is ranked worse than 100% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32
vs STU:MYD: -4.66
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Myriad Genetics Debt-to-EBITDA Related Terms
Myriad Genetics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MYD vs FLGT, CSTL, BDSX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Myriad Genetics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myriad Genetics Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Myriad Genetics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Myriad Genetics (STU:MYD) has a Debt-to-EBITDA of -2.02 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Myriad Genetics. According to the industry distribution chart, Myriad Genetics ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry.
Is Myriad Genetics' Debt-to-EBITDA too high?
Myriad Genetics' current Debt-to-EBITDA is -2.02. Based on the distribution chart, Myriad Genetics ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Myriad Genetics has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Debt-to-EBITDA compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #999999 out of 114 companies for Debt-to-EBITDA. This places Myriad Genetics in the lower half of its industry. The industry median Debt-to-EBITDA is 2.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.32, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Myriad Genetics. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current Debt-to-EBITDA is -2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €10.07, compared to a current price of €2.60 — trading 74.2% below its estimated fair value. The current Debt-to-EBITDA is -2.02. Myriad Genetics' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Debt-to-EBITDA is -2.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €2.60 is trading 74.2% below its estimated GF Value™ of €10.07.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
Debt-to-EBITDA: -2.02
GF Value™: €10.07 vs. price of €2.60 (74.2% below fair value)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
59GF Score
Get the complete analysis for STU:MYD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
